Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS)
FDA's two designations demonstrate KER-0193's potential as a treatment for FXS
Follows the successful completion of Phase 1 clinical trial
Fragile X syndrome is the most common cause of inherited autism
LONDON, May 14, 2025 /PRNewswire/ -- Kaerus Bioscience ("Kaerus" or "the Company"), a clinical stage biopharmaceutical company created by Medicxi for the development of therapeutics for rare genetic syndromes of neurodevelopment, today announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the U.S. Food and Drugs Administration (FDA).
It follows the recent successful completion of a Phase 1 trial of KER-0193 in healthy volunteers, which confirmed the drug to be safe, well tolerated and exhibit excellent pharmacokinetics.
FXS is an inherited condition, affecting about 1 in 7,000 males and 1 in 11,000 females, for which there are currently no approved treatments. It is the most common cause of inherited autism and intellectual disability, accounting for approximately 1 per cent of such cases globally.
Dr Robert Ring, CEO of Kaerus Bioscience, said: "The FDA's granting of Orphan Drug Designation and Rare Pediatric Drug Designation for KER-0193 is an important step towards our objective of delivering an effective treatment for people with Fragile X syndrome.
"Not only do these two FDA designations affirm the therapeutic potential of KER-0193 in Fragile X syndrome, they also provide Kaerus with access to significant regulatory and financial incentives as we look to progress the drug through clinical trials and ultimately take it to market."
Paul Sekhri, Chairman of Kaerus Bioscience, said: "These important FDA designations are more excellent news for Kaerus, coming after the impressive Phase 1 results showing KER-0193 to be safe and well-tolerated. These developments put the Company in a superb position as we look to move into Phase 2 trials."
Both FDA programmes are aimed at encouraging the development of treatments for rare diseases.
Discovered by Kaerus, KER-0193 is a novel, orally-bioavailable small molecule designed to specifically address hyper-excitability of brain function commonly associated with Fragile X syndrome. KER-0193 does this by targeting BK channels (calcium-activated potassium channels), which have been described as master regulators of excitability across the nervous system. The genetic cause of FXS is directly linked to a reduction in BK channel function.
Based on its broad efficacy profile in preclinical genetic models of FXS, Kaerus is excited by the therapeutic potential of KER-0193 to address the diversity of behavioural, sensory and cognitive challenges that adversely impact the lives of individuals with FXS.
Kaerus's conviction has been strengthened by a pre-planned sub-study, conducted during the Phase 1 trial, in which the effects of KER-0193 on brain activity in healthy volunteers were investigated using electroencephalography (EEG). The study convincingly demonstrated that KER-0193 enters the brain and produces pharmcodynamic effects on brain activity in regions often implicated in patients with FXS. These results replicated observations from EEG profiling of KER-0193 in preclinical animal studies, demonstrating proof of mechanism.
Beyond FXS, reduced BK channel activity has been implicated in a number of other neurological conditions, including epilepsy and several rare genetic epileptic encephalopathies.
Dr Ring said: "We are actively exploring opportunities to expand the therapeutic potential of our BK modulator platform to these other indications, where patient populations struggle with significant unmet treatment needs."
The company is finalising preparations for a Phase 2 proof-of-concept study in FXS patients.
About Kaerus
Backed by Medicxi, Kaerus Bioscience Ltd is a clinical-stage biotechnology company committed to turning scientific advances into treatment realities for patients with rare genetic syndromes of neurodevelopment. Kaerus has developed a pipeline of targeted, small molecule therapeutics that address an underlying ion channel dysfunction in Fragile X syndrome, which is the most common inherited cause of intellectual disability and autism globally.
For more information about Kaerus, please visit www.kaerusbio.com
About KER-0193
KER-0193 is a novel, proprietary, and orally-bioavailable small molecule modulator of BK channels discovered by Kaerus. KER-0193 specifically addresses abnormal function of BK channels linked to the genetic cause of Fragile X syndrome. KER-0193 has already demonstrated broad effects on improving syndrome-relevant behavioural, sensory and cognitive deficits observed in genetic animal models of Fragile X. Fragile X syndrome, which affects about 1 in 7,000 males and 1 in 11,000 females, is the most common inherited cause of autism and intellectual disability globally. There are currently no approved treatments for Fragile X.
About Medicxi
Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfil a clear unmet medical need.For more information, please visit: https://www.medicxi.com
View original content:https://www.prnewswire.com/news-releases/kaerus-biosciences-lead-candidate-ker-0193-granted-orphan-drug-designation-and-rare-pediatric-drug-designation-by-us-fda-for-treatment-of-fragile-x-syndrome-fxs-302454471.html
SOURCE Kaerus Bioscience
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Wall Street Journal
19 minutes ago
- Wall Street Journal
Voyager Technologies Rises in Debut, Signaling Improving IPO Market
Shares of space and defense technology company Voyager Technologies surged in their New York Stock Exchange debut Wednesday, another sign of an improving market for initial public offerings. The stock ended the regular session at $56.48 and was up 6% after hours to $60.15.


Skift
21 minutes ago
- Skift
Planners Fear Immigration Crackdowns Will Make Hotel Labor Shortages Worse: Exclusive Survey
The hospitality industry has struggled with a labor shortage since the Covid pandemic. Now, immigration enforcement and an anti-immigrant sentiment are adding a new layer of complexity. An exclusive Skift Meetings survey of U.S. planners shows that they expect to grapple with the effects of Trump-era immigration policies on their events, with growing concern about hotel staffing across the board. More than two-thirds of respondents (72%) said they expect hotel staffing to be affected in 2025–2026 because of immigration policies. Only 13% foresaw no impact. 'Hotel staffing never fully bounced back after the pandemic. We're still experiencing some gaps in service in certain markets and at certain properties,' said Kyle Jordan, director of meetings at the Institute for Operations Research and Management Sciences (INFORMS). Staffing issues are being felt at more than hotels. 'Challenges extend to other key partners like AV providers and vendors that support our meetings,' said Jordan. 'While it's hard to predict the full impact, I would expect that deportation activity could further strain staffing in some destinations.' Concerns stem not just from general staffing shortages but also the effect of revived immigration enforcement policies. 'The main issue is that for many workers in hotels, while they may be legal immigrants, the feeling toward immigrants in general has turned toxic,' said Mark Phillips, CEO of LamontCo. 'No one wants to live and work in such an environment or put families through it, so over time we will see less available even legal immigrant workforces. It already appears to be happening in several cities.' ICE Raids and Protests Exacerbate Immigration Issues In Los Angeles, several days of protests followed large-scale immigration raids by ICE. Protests have spread to other U.S. cities, including Atlanta, Chicago, Washington, D.C, and New York City. a'The hospitality industry relies heavily on immigrant labor especially in back-of-house roles like housekeeping, food and beverage service, and maintenance. Stricter immigration enforcement, increased deportations, and general anti-immigration rhetoric have created fear and uncertainty among these workers, not to mention ICE raids, and I-9 audits. This leads some to leave the industry or self-deport, reducing the labor pool, making it even harder for hotels to fill critical positions,' said Robert Kraus, founder of Small Conferences. Kraus added that there are concerns about the future of the H-2B visa program and similar initiatives. 'There's also a worry that H-2B visas and other temporary worker programs will be curtailed plus general apprehension on potential workers to risk coming to the U.S. just to be told they can't enter or later be sent home only after a short amount of time. This could easily limit the number of foreign workers applying, which is critical for meeting seasonal demands of resorts and other hospitality businesses.' Labor shortages have already disrupted event logistics.'In several cases, my groups suffered through multi-hour lunch services because the hotel restaurant kitchen could not keep up with demand,' he said. Legal Compliance Doesn't Eliminate Anxiety Michael Dominguez, president and CEO of ALHI, argues that deportation is not necessarily a direct impact to hotel staffing. 'It has been required by law for any employee to complete an I-9 form, which verifies legal status and requires documentation,' said Dominguez. 'Any company or hotel not doing that is in violation of Section 274A of the Immigration and Nationality Act of 1986. Everyone working in a hotel needs documentation, or they are breaking the law.' Still, legal status does not erase worker anxiety, said Melanie Nathan, human rights advocate and executive director of the African Human Rights Coalition. 'I know people who are perfectly legal and who have filled in those I-9's who are too scared to go to work. They are standing back to try and ride out what they feel like is a storm. Some fear they might get picked up in workplaces where there are likely to be raids.' Guest Services and Sales Take a Hit The staffing crunch is also affecting guest experience and hotel revenue. 'Daily housekeeping is no longer a given. There are hotels where it is now every other day or on request,' said Akshar Patel, VP of corporate strategy and development at eShow Event Management Solutions and a hospitality expert. Beyond guest services, the staffing crunch is slowing business development efforts. 'A staffing shortage on the sales side is delaying RFPs,' said Patel. Andrea Milrad Heilweil, VP of sales and marketing at The Hutton Group, agrees. 'I have found that since Covid I have to be much more proactive with follow-up. Between people furloughed, laid off, or leaving the industry altogether, RFP responses, requests for contracts, setting up site visits, and general communication have been delayed.'


CBS News
21 minutes ago
- CBS News
Dr. Macquline King named interim Chicago Public Schools CEO by Board of Education
The Chicago Board of Education selected City Hall employee Dr. Macquline King to be the interim CEO of Chicago Public Schools. The board voted on her appointment Wednesday. King will replace outgoing CPS CEO Pedro Martinez, who the board voted out in December 2024 amid an ongoing battle with Mayor Brandon Johnson over funding for the city's public school system. In September 2024, Martinez said he refused a request from Johnson to resign from his post after he declined the mayor's request to take out a $300 million high-interest short-term loan to pay for the costs of the proposed new Chicago teachers' contract and pension costs previously covered by the city. The entire previous school board resigned in October after being pressured by the mayor to fire Martinez. Johnson chose a new school board within days. In November, 10 new members of the school board were elected by the people of Chicago. CPS has been searching for a new permanent head for the district ever since, and a new permanent head has yet to be selected. So far, Dr. King is only the interim CPS CEO. She currently serves as the senior director of educational policy at City Hall. CPS faces a deficit of over half a billion dollars for the 2026 fiscal year, which begins July 1.